Background: Triple-negative breast cancer (TNBC) patients are a poor prognostic subgroup, and currently, there is no biomarker for targeted therapy.
introduction Triple-negative breast cancers (TNBC) are defined as those tumors that lack expression of genes for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor type 2 (HER2). The majority of TNBCs also have a basal phenotype, which has previously been defined by microarray gene-expression studies [1] . TNBC with expression of cytokeratin 5/6 (CK5/6) and/or HER1 (epidermal growth factor receptor; EGFR), according to immunohistochemistry (IHC), are now considered to have a surrogate basal-phenotype, as defined by microarray [2] . However, as TNBC is heterogeneous, a basal marker alone is insufficient for understanding its tumor biology.
As TNBC is unlikely to benefit from existing targeted therapies, such as endocrine therapy and trastuzumab, conventional chemotherapies are used for its treatment. However, the sensitivity of TNBC to chemotherapy varies, with ∼30% of these breast cancer patients achieving complete pathological response with neoadjuvant chemotherapy [3] .
Approximately 20% of breast cancers harbor PIK3CA mutation, which permits cell growth independent to epidermal growth factors. Thus, it has been hypothesized that PIK3CA may have a role in cell survival in TNBC, but its impact on the prognosis of breast cancer patients is controversial [4, 5] . Functional loss of the phosphatase and tensin homolog (PTEN), which is known as a negative regulator of the phosphoinositide 3-kinase (PI3K) signaling pathway, may play a role in activating the PI3K/AKT pathway [6] . The frequency of AKT1 mutation (E17K) in breast cancer is reportedly 8%, which has been shown to lead to higher kinase activity than that of wild-type AKT1 [7] . Therefore, AKT integrates various upstream inputs and triggers downstream network activities [8] . The mitogen-activated protein kinase (MAPK)-MAPK kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade also has a fundamental function in the regulation of cell proliferation and survival. Aberrant functioning of MAPK is related to tumorigenesis, and crosstalk between the PI3K/AKT and MAPK pathways has been implicated. ERK1 and ERK2 (ERK1/2) exist downstream of *Correspondence to: Dr Kenji Tamura, Department of Breast Oncology and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. Tel: +81-3-3542-2511; Fax: +81-3-3542-3815; E-mail: ketamura@ncc.go.jp MAPK signaling and integrate various upstream signal transductions [9] .
Previous studies have demonstrated that these signal cascades are up-regulated in TNBC [8] . However, the role(s) of these cascades in TNBC and how they are activated by their upstream receptors are unknown. In this study, we used TNBC samples to identify biomarkers that up-regulate PI3K/AKT or MAPK pathways in relation to patients' clinical outcomes.
patients and methods patients
Patients included in this analysis had to meet the following criteria: breast cancer patients who underwent lumpectomy or mastectomy between 2002 and 2008 at the National Cancer Center Hospital; who received at least one regimen of adjuvant chemotherapy following breast surgery; who were pathologically identified to have at least one axillary lymph-node metastasis; who had no history of previous chemotherapy or endocrine therapy; and diagnosed with TNBC. TNBC was defined as ER-negative, PgR-negative, and HER2-negative [10, 11] .
immunohistochemistry and polymerase chain reaction
We used both primary FFPE tumor samples and methanol-fixed paraffinembedded metastatic lymph-node samples for gene mutation analysis. For IHC, 4-μm-thick sections of whole tissue were deparaffinized in xylene and rehydrated in ethanol. All sections were incubated in 3% hydrogen peroxidase in 100% methanol for 30 min to remove endogenous peroxidase activity. All antibodies information and IHC conditions are listed in supplementary Table S1 , available at Annals of Oncology online. A substrate-chromogen mix was used for visualization of the immunoreactions. Meyer's sour hematoxylin was used as the counter stain. Evaluation of IHC was performed by two authors (KH and HT) who were initially blind to the clinical information. original articles
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For evaluation of phospho-AKT ( pAKT), phospho-ERK ( pERK), and PTEN, presentation of >10% of positive cancer cells was considered positive for each marker, and tumors were graded according to the staining intensity, where 0, no staining; 1, light staining; 2, moderate staining; and 3, strong staining (supplementary Figures S2 and S3, available at Annals of Oncology online). For HER1, HER3, and insulin-like growth factor receptor-1 (IGF1R), we applied the evaluation methods used previously for HER2 [11] . For HER4, both membrane, cytoplasmic, and nuclear immunoreactivity were evaluated. Phosphorylated HER4 was also evaluated by two different antibodies ( pTyrY1162 and pTyrY1188) in cytoplasm and in nuclei (supplementary Figures S4 and S5, available at Annals of Oncology online). For evaluation of CK5/6 and aldehyde dehydrogenase 1 (ALDH1), the presence of >5% positive cancer cells was considered positive for each marker.
Genomic DNA was extracted after macro-dissection of tissues, using hematoxylin-eosin stain as a reference marker. PIK3CA gene mutations in exon 9 (E542K, E545K/D) or exon 20 (H1047R) were detected with an ARMS/Scorpions primer PI3K mutation test kit (PK01; QIAGEN, Tokyo, Japan) [12] . For AKT1 mutation analysis, we designed the following primer pair to detect E17K mutation: forward primer, 5 0 -ATCCCAGGCACATC TGTCCT-3 0 , and reverse primer, 5 0 -TAGGACTCAGCCTGGAGACT-3 0 .
statistical analysis
Detection of the associations of each biomarker examined in this analysis was carried out using the χ 2 tests. Event-free survival (EFS) was defined as the time from surgery until the detection of recurrence or death due to any cause. The overall survival (OS) was defined as the time from surgery until the date of death or the most recent follow-up. The median EFS and median survival time (MST) were calculated using the Kaplan-Meier method, and significance was determined using the log-rank test. The significant differences between variables were determined with two-sided t-tests, and these calculations were carried out with SPSS, version 19 (IBM, Okinawa, Japan).
results patient characteristics and biomarkers
We identified 75 TNBC patients who met the eligibility criteria. The characteristics of these patients are listed in Table 1 . Anthracycline-containing regimens included doxorubicin and cyclophosphamide or epirubicin, fluorouracil, and cyclophosphamide. Taxane-containing regimens included paclitaxel or docetaxel.
gene mutation assay and immunohistochemical study Table 2 shows the frequency of expression or mutation of each biomarker. We found that 26 tumors (35%) harbored PIK3CA mutations, of which 15 were of H1047R and 11 were of E545K. Expression level n -n ---n ----n --n n n ----n n n -n -n --n n n n --n --n --nn n ---n -n -n ----n ----n ----n -n ---n n pAKT + + + + + + + + + + + + + + + + + + + + + + + + + +- In contrast, no AKT1 mutations were detected in 45 samples that were successfully sequenced. Expression of each marker in accordance with PIK3CA and AKT1 mutations are shown in Figure 1 . Subsequently, we examined which factors may contribute to activation of the PI3K/AKT or MAPK pathways. We found that pAKT was related to HER4 expression (membrane, P = 0.004; cytoplasmic, P = 0.001) and phosphorylated HER4 in cytoplasm (P = 0.04) ( Table 3) . pERK was related to cytoplasmic pHER4 expression (P = 0.01). Among the correlations examined, HER1 and IGF1R (P = 0.001) were significantly related to each other.
survival analysis
We analyzed pAKT and pERK in relation to EFS and OS in a median follow-up period of 63.2 months. The median EFS of those patients with pAKT positivity or negativity was not reached until or 79.4 months, respectively (P = 0.024) (Figure 2A ). For OS, we did not detect a significant difference between the pAKT groups. Furthermore, the tumors that were pAKT-positive or -negative were not statistically different in terms of the number of lymph-node metastases (1-3 versus ≥4), T-stage (T1-2 versus T3-4), tumor grade (grade 1-2 versus 3), or chemotherapy regimens (anthracycline followed by taxanes versus others). Because HER4 and pAKT were significantly correlated with each other (Table 3) , we then assessed HER4 expression with regard to EFS and OS. The median EFS for patients with HER4-positive tumors was significantly longer than that for patients with HER4-negative tumors (membrane: not reached versus 79.4 months, P = 0.03; cytoplasmic: not reached versus 89.7 months, P = 0.04, nuclear: not reached versus 86.2 months, P = 0.03) ( Figure 2B ). Phosphorylated HER4 was prone to good prognosis in EFS, although statistical significance was not identified (cytoplasmic: P = 0.077, nuclear: P = 0.279). Regarding OS, both HER4 and pHER4 expressions were not a factor for survival. The tumors that were HER4-positive or -negative were statistically different in terms of the number of lymph-node metastases [number of metastases in HER4-positive tumors, 1-3 (77%) versus ≥4 (23%), P = 0.02], but not in terms of T-stage, tumor grade, and chemotherapy regimens.
We also found that both EFS and OS were significantly longer for patients with pERK-positive tumors than for those with pERK-negative tumors (median EFS; not reached versus 62.2 months, P = 0.002, MST; not reached versus not reached, P = 0.006, respectively) ( Figure 2C and D) . However, no differences were found in pERK-positive versus -negative tumors in terms of the following criteria: number of lymph-node metastases, T-stage, tumor grade, or chemotherapy regimen. PIK3CA mutation status was not correlated with EFS and OS, although this was associated with basal marker.
In univariate analysis for EFS, T-stage (3 versus others), number of lymph node (>3 versus 1-3), pAKT, pERK, and pHER4 (cytoplasmic) were statistically significant good prognostic marker (Table 4) . In multivariate analysis, pERK and T-stage (1-3 versus >3) remained as good prognostic marker.
discussion
In this biomarker analysis aimed to explore potential therapeutic targets of TNBC, we determined both that HER4 expression is associated with phosphorylated AKT expression, and that tumors expressing either HER4 or pAKT were associated with patients with better prognosis. Furthermore, tumors that expressed phosphorylated ERK were also associated with better prognosis than tumors lacking pERK.
HER4 has been reported as a good prognostic marker in breast cancers not limited to the triple-negative subtype. Witton et al. [13] reported that HER4 is the only good prognostic marker, whereas other HER family members are negatively related to survival, possibly because HER4 is related to ER positivity and low tumor grade. Of note, we examined the HER4 expression pattern in both the membrane, the cytoplasm, and nuclear, because the intracellular domain of HER4 has been reported as a good prognostic factor [14, 15] . For phosphorylated HER4 ( pHER4), we used two different antibodies ( pTyrY1162 and pTyrY1188) (supplementary Figures S4 and  S5 , available at Annals of Oncology online). We confirmed the specificity of these antibodies by abolition of staining following pre-incubation of them with the phospho peptide (0.1 mg/ml, Abnova) (Supplementary Figure S6 , available at Annals of Oncology online). HER4 expressions were detected both in membrane, in cytoplasm, and in nuclei. In contrast, pHER4 expressions were detected in cytoplasm and nuclei, but not in membrane. HER4 levels in all subcellular localization were associated with good prognosis in EFS. Cytoplasmic and nuclear pHER4 levels were prone to good prognosis but not statistically Figure S7 , available at Annals of Oncology online). HER4 may play a role in the process that leads to apoptosis or decreased activity of cell proliferation, such that tumors that express HER4 may be associated with a good prognosis [15] . Previously, some studies have reported activation of the PI3K/ AKT or MAPK pathways as a negative prognostic factor, whereas others have reported that these factors did not relate to survival [16] . Furthermore, ALDH-1, a potential stem cell marker in breast cancer, has also been reported as a negative prognostic marker in breast cancer, whereas IGF1R expression and PIK3CA mutation are reportedly related to better clinical outcomes [4, [17] [18] [19] . Regarding the MAPK pathway, there was a previous report that the expression level of MAPK was related to chemosensitivity in hormone receptor-negative tumors [20] . In contrast, other reports have suggested that activation of the MAPK pathway is associated with chemoresistance [16] . These discrepant results from previous reports may be due to the selection of the breast cancer cohorts. In this study, we limited enrollment to unique TNBC patients who had lymph-node metastases, whereas some other studies have included skewed breast cancer subtypes. Thus, the possibility remains that previous results may reflect the outcomes of poor-prognosis subgroups, including triple-negative or HER2-subtypes, as these markers seem highly related to triple-negative or HER2-subtypes rather than to hormone receptor-positive subtypes [18, 21] . In this study, PIK3CA mutation status was not correlated with survival, although this was associated with basal marker positive which was already reported to be chemo-sensitive. Phosphorylated Akt would be affected not only by PI3CA mutation but also by AKT1 mutation, PTEN loss, or MAGI3-Akt3 fusion gene. The discrepancies with prognosis from the previous reports might be influenced chemosensitivities which are related with pERK, PI3CA, or AKT1 mutation status, because all presented patients have received adjuvant chemotherapies.
Interpretation of the present results should be done cautiously because this study has some limitations. First, patients included in this analysis were pathologically identified as having lymphnode-positive TNBCs. Generally, the primary tumor size and the number of lymph-node metastases are significant prognostic factors in breast cancer. However, in lymph node-positive TNBCs, prognosis may not be affected by the number of lymphnode metastases. Secondly, chemotherapy containing anthracycline followed by taxanes may benefit TNBC patients. To reduce this factor, we carried out the χ 2 tests for each biomarker to identify prognostic factors relevant by the number of lymphnode metastases, tumor size, tumor grade, and chemotherapy regimens.
In summary, we revealed a correlation between HER4 and pAKT expression, and found that both factors were associated 
